What has SMC said?
The Scottish Medicines Consortium (SMC) has accepted cemiplimab used by itself (as monotherapy) for the first-line treatment of adults with non-small cell lung cancer (NSCLC). It is used where the tumour cells have no mutations in the genes EGFR, ALK or ROS1, and 50% or more of the tumour cells have a protein called PD-L1.
SMC has accepted cemiplimab for restricted use. The restriction means that it is accepted for use only in those patients described above who have locally advanced NSCLC that cannot be effectively treated with chemotherapy and radiotherapy used together (chemoradiation). Treatment with cemiplimab can be continued for up to 36 three-weekly cycles.
This document summarises the SMC decision and what it means for patients.
You can find more detailed information about the SMC assessment of cemiplimab by looking at the SMC Detailed Advice Document (SMC2905).
What does SMC’s decision mean for patients?
Cemiplimab for use as described above is available for prescribing on the NHS in Scotland. Your healthcare professional can discuss with you if it is the right treatment for you.
You can find more information about making decisions about your treatment here: Medicines in Scotland: What’s the right treatment for me?
More about SMC’s decision
SMC’s decision takes into account a confidential discount offered by the pharmaceutical company.
How does SMC make its decision?
SMC carefully considers every new medicine to make sure it benefits patients and is likely to be a good use of NHS resources.
To do this SMC studies the following:
- Evidence from the company about how well the medicine works compared with current treatments available in Scotland, in relation to how much they will cost to buy and use to treat patients.
- Information from patient groups about the potential impact of the medicine on patients and carers.
- Advice from healthcare professionals about any benefits of the new medicine compared to current treatment, along with how the new medicine is likely to be used.
When SMC assesses a medicine it takes account of the needs of all patients in NHSScotland, not only those who may be treated with the medicine.
You can find out more about how SMC decides here: https://www.scottishmedicines.org.uk/how-we-decide/
More information and support
The organisation below can provide more information and support for people living with lung cancer and their families. SMC is not responsible for the content of any information provided by external organisations.
Roy Castle Lung Cancer Foundation
https://roycastle.org 0800 358 7200
You can find out more about cemiplimab (brand name: Libtayo®) in the Patient Information Leaflet (PIL) by searching for the medicine name on the Medicines and Healthcare products Regulatory Agency (MHRA) website.
https://products.mhra.gov.uk/